Product Description
Cabazitaxel is a type of chemotherapy. You might have it as a treatment for prostate cancer that has spread (advanced prostate cancer). Cabazitaxel works by stopping cancer cells from separating into two new cells. This blocks the growth of the cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/cabazitaxel)
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Oncology Solid Tumor Unspecified | Prostate Cancer | Oncology Unspecified
Known Adverse Events: Abdominal Pain | Back Pain | Dysgeusia | Pain Unspecified | Alopecia | Anemia | Leukopenia | Thrombocytopenia | Neutropenia | Arthralgia | Hematuria | Dyspnea | Anorexia | Asthenia | Constipation | Diarrhea
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Canada, Denmark, France, Germany, Italy, Poland, Spain, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Prostate Cancer
Phase 2: Adenocarcinoma|Oncology Unspecified
Phase 1: Glioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-001928-54 | P2 |
Active, not recruiting |
Prostate Cancer |
2028-12-27 |
|
| CA209650 | P2 |
Unknown Status |
Prostate Cancer |
2026-10-08 |
|
| AVPC | P2 |
Active, not recruiting |
Prostate Cancer |
2025-06-30 |
|
| PCCTC LOI: c12-108 | P2 |
Completed |
Prostate Cancer |
2023-10-13 |